No. <sup>(b)</sup>	Mechanism <sup>(c)</sup>	Reaction rate law/rule <sup>(d)</sup>
r01	CyclinB + CDK1 <-> [CDK1:CyclinB]	kb_CyclinB_CDK1*CyclinB*CDK1 - kub*[CDK1:CyclinB]
r02	CyclinB + CDK1_pY15 <-> [CDK1_pY15:CyclinB]	kb_CyclinB_CDK1*CyclinB*CDK1_pY15 - kub*[CDK1_pY15:CyclinB]
r03	[CDK1:CyclinB] -> [CDK1_pT161:CyclinB]	Vm_CAK_CDK1B*[CDK1:CyclinB]/(km_CAK_CDK1B +[CDK1:CyclinB])
r04	[CDK1_pY15:CyclinB] -> [CDK1_pY15_pT161:CyclinB]	Vm_CAK_CDK1B*[CDK1_pY15:CyclinB]/(km_CAK_CDK1B+ [CDK1_pY15:CyclinB])
r05	[CDK1_pT161:CyclinB] -> [CDK1:CyclinB]	kdp*[CDK1_pT161:CyclinB]
r06	[CDK1_pY15_pT161:CyclinB] -> [CDK1_pY15:CyclinB]	kdp*[CDK1_pY15_pT161:CyclinB]
r07	Wee1 + [CDK1:CyclinB] <-> [Wee1:(CDK1:CyclinB)]	kb_Wee1_CDK1B*Wee1*[CDK1:CyclinB] - kub*[Wee1:(CDK1:CyclinB)]
r08	[Wee1:(CDK1:CyclinB)] -> Wee1 + [CDK1_pY15:CyclinB]	kcat_Wee1_CDK1B*[Wee1:(CDK1:CyclinB)]
r09	Wee1 + [CDK1_pT161:CyclinB] <-> [Wee1:(CDK1_pT161:CyclinB)]	kb_Wee1_CDK1B*Wee1*[CDK1_pT161:CyclinB] - kub*[Wee1:(CDK1_pT161:CyclinB)]
r10	[Wee1:(CDK1_pT161:CyclinB)] -> Wee1 + [CDK1_pY15_pT161:CyclinB]	kcat_Wee1_CDK1B*[Wee1:(CDK1_pT161:CyclinB)]
r11	[CDK1_pT161:CyclinB] + Wee1 <-> [(CDK1_pT161:CyclinB):Wee1]	kb_CDK1B_Wee1*[CDK1_pT161:CyclinB]*Wee1 - kub*[(CDK1_pT161:CyclinB):Wee1]
r12	[(CDK1_pT161:CyclinB):Wee1] -> [CDK1_pT161:CyclinB] + Wee1_pT123	kcat_CDK1B_Wee1*[(CDK1_pT161:CyclinB):Wee1]
r13	Wee1_pT123 -> Wee1	kdp*Wee1_pT123
r14	PLK1_pT210 + Wee1_pT123 <-> [PLK1_pT210:Wee1_pT123]	kb_PLK1P_Wee1*PLK1_pT210*Wee1_pT123 - kub*[PLK1_pT210:Wee1_pT123]
r15	[PLK1_pT210:Wee1_pT123] -> PLK1_pT210	kcat_PLK1P_Wee1*[PLK1_pT210:Wee1_pT123]
r16	AuroraA_pT288 + CDC25 <-> [AuroraA_pT288:CDC25]	kb_AuroraAP_CDC25*AuroraA_pT288*CDC25 - kub*[AuroraA_pT288:CDC25]
r17	[AuroraA_pT288:CDC25] -> AuroraA_pT288 + CDC25_pS	kcat_AuroraAP_CDC25*[AuroraA_pT288:CDC25]
r18	PLK1_pT210 + CDC25 <-> [PLK1_pT210:CDC25]	kb_PLK1P_CDC25*PLK1_pT210*CDC25-kub*[PLK1_pT210:CDC25]
r19	[PLK1_pT210:CDC25] -> PLK1_pT210 + CDC25_pS	kcat_PLK1P_CDC25*[PLK1_pT210:CDC25]
r20	[CDK1_pT161:CyclinB] + CDC25 <-> [(CDK1_pT161:CyclinB):CDC25]	kb_CDK1B_CDC25*[CDK1_pT161:CyclinB]*CDC25-kub*[(CDK1_pT161:CyclinB):CDC25]
r21	[(CDK1_pT161:CyclinB):CDC25] -> [CDK1_pT161:CyclinB] + CDC25_pS	kcat_CDK1B_CDC25*[(CDK1_pT161:CyclinB):CDC25]

Table S1. List of biochemical reactions and related reaction rate in the computational model<sup>(a)</sup>.

r22	CDC25_pS -> CDC25	kdp*CDC25_pS
r23	CDC25_pS + [CDK1_pY15:CyclinB] <-> [CDC25_pS:(CDK1_pY15:CyclinB)]	kb_CDC25_CDK1B*CDC25_pS*[CDK1_pY15:CyclinB]-kub*[CDC25_pS:(CDK1_pY15:CyclinB)]
r24	[CDC25_pS:(CDK1_pY15:CyclinB)] -> CDC25_pS + [CDK1:CyclinB]	kcat_CDC25_CDK1B*[CDC25_pS:(CDK1_pY15:CyclinB)]
r25	CDC25_pS + [CDK1_pY15_pT161:CyclinB] <->	kb_CDC25_CDK1B*CDC25_pS*[CDK1_pY15_pT161:CyclinB] -
	[CDC25_pS:(CDK1_pY15_pT161:CyclinB)]	kub*[CDC25_pS:(CDK1_pY15_pT161:CyclinB)]
r26	[CDC25_pS:(CDK1_pY15_pT161:CyclinB)] -> CDC25_pS + [CDK1_pT161:CyclinB]	kcat_CDC25_CDK1B*[CDC25_pS:(CDK1_pY15_pT161:CyclinB)]
r27	AuroraA + AuroraA <-> [AuroraA:AuroraA]	kb_AuroraA_AuroraA*AuroraA - kub*[AuroraA:AuroraA]
r28	[AuroraA:AuroraA] -> AuroraA_pT288 + AuroraA	kcat_AuroraA_AuroraA*[AuroraA:AuroraA]
r29	AuroraA_pT288 + AuroraA <-> [AuroraA_pT288:AuroraA]	kb_AuroraAP_AuroraA*AuroraA_pT288*AuroraA - kub*[AuroraA_pT288:AuroraA]
r30	[AuroraA_pT288:AuroraA] -> AuroraA_pT288 + AuroraA_pT288	kcat_AuroraAP_AuroraA*[AuroraA_pT288:AuroraA]
r31	AuroraA_pT288 + PLK1 <-> [AuroraA_pT288:PLK1]	kb_AuroraAP_PLK1*AuroraA_pT288*PLK1 - kub*[AuroraA_pT288:PLK1]
r32	[AuroraA_pT288:PLK1] -> AuroraA_pT288 + PLK1_pT210	kcat_AuroraAP_PLK1*[AuroraA_pT288:PLK1]
r33	Bora + PLK1 <-> [Bora:PLK1]	kb_Bora_PLK1*Bora*PLK1 - kub*[Bora:PLK1]
r34	AuroraA_pT288 + [Bora:PLK1] -> [AuroraA_pT288:(Bora:PLK1)]	kb_AuroraAP_BoraPLK1*AuroraA_pT288*[Bora:PLK1]
r35	[AuroraA_pT288:(Bora:PLK1)] -> AuroraA_pT288 + Bora + PLK1_pT210	kcat_AuroraAP_BoraPLK1*[AuroraA_pT288:(Bora:PLK1)]
r36	PLK1_pT210 -> PLK1	kdp*PLK1_pT210
r37	PLK1_pT210 + Bora <-> [PLK1_pT210:Bora]	kb_PLK1P_Bora*PLK1_pT210*Bora - kub*[PLK1_pT210:Bora]
r38	[PLK1_pT210:Bora] -> PLK1_pT210	kcat_PLK1P_Bora*[PLK1_pT210:Bora]
r39	ATR -> ATR_active	kcat_damage*ATR
r40	Claspin + CHK1 <-> [Claspin:CHK1]	kb_Claspin_CHK1*Claspin*CHK1 - kub*[Claspin:CHK1]
r41	ATR_active + [Claspin:CHK1] -> [ATR_active:(Claspin:CHK1)]	kb_ATR_ClaspinCHK1*ATR_active*[Claspin:CHK1]
r42	[ATR_active:(Claspin:CHK1)] -> ATR_active + Claspin + CHK1_pS	kcat_ATR_ClaspinCHK1*[ATR_active:(Claspin:CHK1)]
r43	CHK1_pS -> CHK1	kdp*CHK1_pS

r44	CHK1_pS + CDC25 <-> [CHK1_pS:CDC25]	kb_CHK1_CDC25*CHK1_pS*CDC25 - kub*[CHK1_pS:CDC25]
r45	[CHK1_pS:CDC25] -> CHK1_pS + CDC25_ppp	kcat_CHK1_CDC25*[CHK1_pS:CDC25]
r46	[14-3-3] + CDC25_ppp <-> [14-3-3:CDC25_ppp]	kb_1433_CDC25*[14-3-3]*CDC25_ppp - kub*[14-3-3:CDC25_ppp]
r47	CDC25_ppp -> CDC25	kdp*CDC25_ppp
r48	PLK1_pT210 + Claspin <-> [PLK1_pT210:Claspin]	kb_PLK1P_Claspin*PLK1_pT210*Claspin - kub*[PLK1_pT210:Claspin]
r49	[PLK1_pT210:Claspin] -> PLK1_pT210	kcat_PLK1P_Claspin*[PLK1_pT210:Claspin]
r50	null -> CyclinB	ks_CyclinB*(CyclinB_max-CyclinB_total)/(CyclinB_max*CyclinB_total)
r51	null -> AuroraA	ks_AuroraA*(AuroraA_max-AuroraA_total)/(AuroraA_max*AuroraA_total)
r51 r52	null -> AuroraA null -> Bora	ks_AuroraA*(AuroraA_max-AuroraA_total)/(AuroraA_max*AuroraA_total) ks_Bora*(Bora_max-Bora_total)/(Bora_max*Bora_total)
r51 r52 r53	null -> AuroraA null -> Bora null -> PLK1	ks_AuroraA*(AuroraA_max-AuroraA_total)/(AuroraA_max*AuroraA_total) ks_Bora*(Bora_max-Bora_total)/(Bora_max*Bora_total) ks_PLK1*(PLK1_max-PLK1_total)/(PLK1_max*PLK1_total)
r51 r52 r53 r54	null -> AuroraA null -> Bora null -> PLK1 AuroraA + VX680 <-> [Aurora-A:VX680]	ks_AuroraA*(AuroraA_max-AuroraA_total)/(AuroraA_max*AuroraA_total) ks_Bora*(Bora_max-Bora_total)/(Bora_max*Bora_total) ks_PLK1*(PLK1_max-PLK1_total)/(PLK1_max*PLK1_total) kb_AuroraA_VX*AuroraA* VX680 - kub*[Aurora-A:VX680]
r51 r52 r53 r54 r55	null -> AuroraA null -> Bora null -> PLK1 AuroraA + VX680 <-> [Aurora-A:VX680] AuroraA_pT288 + VX680 <-> [AuroraA_pT288:VX680]	ks_AuroraA*(AuroraA_max-AuroraA_total)/(AuroraA_max*AuroraA_total) ks_Bora*(Bora_max-Bora_total)/(Bora_max*Bora_total) ks_PLK1*(PLK1_max-PLK1_total)/(PLK1_max*PLK1_total) kb_AuroraA_VX*AuroraA* VX680 - kub*[Aurora-A:VX680] kb_AuroraA_VX*AuroraA_pT288* VX680 - kub*[AuroraA_pT288: VX680]
r51 r52 r53 r54 r55 r56	null -> AuroraA   null -> Bora   null -> PLK1   AuroraA + VX680 <-> [Aurora-A:VX680]   AuroraA_pT288 + VX680 <-> [AuroraA_pT288:VX680]   PLK1 + BI2536 <-> [PLK1:BI2536]	ks_AuroraA*(AuroraA_max-AuroraA_total)/(AuroraA_max*AuroraA_total) ks_Bora*(Bora_max-Bora_total)/(Bora_max*Bora_total) ks_PLK1*(PLK1_max-PLK1_total)/(PLK1_max*PLK1_total) kb_AuroraA_VX*AuroraA* VX680 - kub*[Aurora-A:VX680] kb_AuroraA_VX*AuroraA_pT288* VX680 - kub*[AuroraA_pT288: VX680] kb_PLK1_BI*PLK1*BI2536 - kub*[PLK1:BI2536]

<sup>(a)</sup> An idealized cell may be considered as a sphere with a diameter of  $1.25 \times 10^{-5}$  m, resulting in a cell volume of roughly  $2 \times 10^{-12}$  L. Given a typical concentration of a specific protein to be 1 nM, we calculate the total protein number of  $1.2 \times 10^{3}$  molecules/cell. For a reaction volume containing  $1.2 \times 10^{3}$  molecules, we are justified in using ordinary differential equations to describe changes in a continuous concentration of molecular species. The concentration of molecular species was in units of molecules/cell. Quantitative analysis of the experimental time series data of the protein levels of molecular species was performed with QuantityOne software (Bio-Rad) as described<sup>1-3</sup>. Biochemical reactions between species of the same proteins (e.g. with different phosphorylation states) were assumed to have the same reaction rate parameters.

<sup>(b)</sup> Description of biochemical reactions:

**r01** and **r02**: Cyclin B and cyclin-dependent kinase 1 (Cdk1) form cyclin B/Cdk1, which is the key regulator of cell cycle progression<sup>4, 5</sup>.  $[CDK1]_{t=0} = 2 \times 10^5$  molecules/cell<sup>6</sup>.

**r03** and **r04**: Phosphorylation of Cdk1 on Thr161 by Cdk-activating kinase (CAK) is required for the complete activation of cyclin B/Cdk1<sup>7</sup>, <sup>8</sup>. The process is mathematically expressed as Michaelis-Menten equations, in which the Michaelis constant  $k_{m\_CAK\_CDK1B}$  is 7.08 × 10<sup>5</sup> molecule, and the maximal reaction rate  $V_{m CAK\_CDK1B}$  is 1.93 × 10<sup>11</sup> (molecule min<sup>-1</sup>)<sup>7</sup>.

r05 and r06: Dephosphorylation of Cdk1-pT161.

- **r07 r10**: Cdk1 is held inactive by the phosphorylation on Thr14 and Tyr15 by kinase Wee1 during the S and G2 phases prior to mitosis<sup>9, 10</sup>. [Wee1]<sub>t=0</sub> = 2.5 × 10<sup>4</sup> (molecules/cell)<sup>11</sup>.
- r11 and r12: Activated cyclin B-Cdk1 phosphorylates Wee1 on Ser123, thereby creating a binding site for kinase Plk1<sup>11-14</sup>.

**r13**: Dephosphorylation of Wee1-pT123.

- **r14** and **r15**: Phosphorylation on Ser123 of Wee1 creates the binding site for the Plk1 PBD domain and accelerates the further phosphorylation of Wee1 by Plk1, which induces the degradation of Wee1 by  $\beta$ -TrCP ubiquitin-proteasome system<sup>12, 14</sup>.
- **r16 r19**: Activated Aurora-A and Plk1 will directly phosphorylate Cdc25 and thereby stimulate its phosphatase activity<sup>15-18</sup>. [Cdc25]<sub>t=0</sub> = 1 × 10<sup>4</sup> (molecules/cell)<sup>11, 19</sup>.
- r20 and r21: Following activation, cyclin B-Cdk1 phosphorylates and activates Cdc25<sup>20, 21</sup>.

r22: Dephosphorylation of Cdc25.

- r23 r26: The dual specificity phosphatase Cdc25 dephosphorylates Thr14 and Tyr15 of Cdk1, thereby activating cyclin B-Cdk1<sup>21-23</sup>.
- r27 r30: During mitotic entry, the kinase activity of Aurora-A depends on the auto-phosphorylation of Thr288 in its T loop<sup>24-26</sup>.

r31 and r32: Activated Aurora-A will phosphorylate Thr210 of Plk1 and thereby promote its activation<sup>27, 28</sup>.

r33 - r35: Bora directly binds to Plk1 and controls the accessibility of its activation loop for phosphorylation, which greatly enhances the activation effect by Aurora-A<sup>27, 28</sup>.

r36: Dephosphorylation of Plk1-pT210.

- **r37** and **r38**: The degradation of Bora depends on Plk1 mediated phosphorylation<sup>29</sup>.
- **r39**: In response to G2 DNA damage, the activity of ataxia–telangiectasia and rad3-related ATR kinase is triggered<sup>30, 31</sup>.  $[ATR]_{t=0} = 2.4 \times 10^3$  (molecules/cell)<sup>32</sup>. To mimic the DNA-damage response, the parameter  $k_{cat\_damage}$  representing ATR activation was set to 0.8; and during checkpoint recovery,  $k_{cat\_damage}$  was reset to zero. These settings give model simulations that are consistent with previous experimental observations<sup>32</sup>.
- **r40 r42**: Activated ATR will phosphorylate and activate checkpoint kinase Chk1, in the assistance of Claspin<sup>33-35</sup>. [Chk1]<sub>t=0</sub> =  $2.4 \times 10^4$  (molecules/cell)<sup>32</sup>.

**r43**: Dephosphorylation of Chk1.

r44 - r46: Once activated, Chk1 will inhibit the phosphatase activity of Cdc25 by phosphorylating and promoting its association with decoy protein 14-3-3 <sup>33, 36, 37</sup>.

r47: Dephosphorylation of Cdc25.

r48 and r49: Plk1-mediated degradation of Claspin by ubiquitin and proteasome system during checkpoint recovery<sup>38-41</sup>.

**r50** – **r53**: **Definition of protein synthesis**. The synthesis of cyclin B, Aurora-A, Plk1 and Bora were formulated as sigmoid functions. The initial values of the corresponding reaction rate parameters (i.e. *ks1\_ProteinName*, *ks2\_ProteinName*) were estimated by fitting to the experimental data. The protein maximum levels (i.e. *ProteinName\_max*) were obtained from previous experimental measurements. It is found that the sigmoid functions give simulation results that are absolutely consistent with experimental values (i.e. the protein expression pattern). Whereas, using a simple method considering only constant rate of protein synthesis and linear protein degradation gives disappointing simulation results that are inconsistent with the experimental values (data not shown).

**r50**: The synthesis of cyclin  $B^{28, 42}$ .

 $[CyclinB_max]_{t=0} = 8 \times 10^3 \text{ (molecules/cell)}^6.$ 

```
[CyclinB\_total] = [(CDK1\_pT161:CyclinB):Wee1] + [(CDK1\_pT161:CyclinB):CDC25] + [CDC25\_pS:(CDK1\_pY15:CyclinB)] + [(CDK1\_pT161:CyclinB):CDC25] + [CDC25\_pS:(CDK1\_pY15:CyclinB)] + [(CDK1\_pT161:CyclinB):CDC25] + [CDC25\_pS:(CDK1\_pY15:CyclinB)] + [(CDK1\_pT161:CyclinB):CDC25] + [CDC25\_pS:(CDK1\_pY15:CyclinB)] + [(CDK1\_pT161:CyclinB):CDC25] + [(CDK1\_pY15:CyclinB)] + [(CDK1\_pT161:CyclinB):CDC25] + [(CDK1\_pY15:CyclinB)] + [(CDK1\_pY15:CyclinB)]
```

 $[CDC25\_pS:(CDK1\_pY15\_pT161:CyclinB)] + [CDK1:CyclinB] + [CDK1\_pT161:CyclinB] + [CDK1\_pY15:CyclinB] + [CDK1\_p$ 

[CDK1\_pY15\_pT161:CyclinB] + [CyclinB] + [Wee1:(CDK1:CyclinB)] + [Wee1:(CDK1\_pT161:CyclinB)].

ks\_CyclinB =  $100.57e^{0.0126T}$ . (Note: *T* is simulation time)

**r51**: The synthesis of Aurora-A<sup>28, 29</sup>.

```
[\text{AuroraA}_{\text{max}}]_{t=0} = 7.2 \times 10^3 \text{ (molecules/cell)}^{24, 43}.
```

```
[AuroraA\_total] = [AuroraA] + 2*[AuroraA:AuroraA] + [AuroraA\_pT288] + [AuroraA\_pT288:(Bora:PLK1)] + 2*[AuroraA] + 2*[AuroraA] + 2*[AuroraA] + [AuroraA\_pT288] + [AuroraA\_pT2
```

```
2*[AuroraA_pT288:AuroraA] + [AuroraA_pT288:CDC25] + [AuroraA_pT288:PLK1].
```

```
ks_AuroraA = 180.38e^{0.0172T}.
```

**r52**: The synthesis of Bora<sup>28, 29</sup>.

 $[Bora\_max]_{t=0} = 4.5 \times 10^3 (molecules/cell)^{28}.$ 

 $[Bora\_total] = [AuroraA\_pT288:(Bora:PLK1)] + [Bora] + [Bora:PLK1] + [PLK1\_pT210:Bora].$ 

```
ks_Bora = 221.95e^{0.0141T}.
```

```
r53: The synthesis of Plk1<sup>28, 29, 44</sup>.
```

```
[PLK1_max]_{t=0} = 9.6 \times 10^3 \text{ (molecules/cell)}^{43, 45}.
```

 $[PLK1\_total] = [AuroraA\_pT288:(Bora:PLK1)] + [AuroraA\_pT288:PLK1] + [Bora:PLK1] + [PLK1] + [PLK1\_pT210] + [PL$ 

[PLK1\_pT210:Bora] + [PLK1\_pT210:CDC25] + [PLK1\_pT210:Claspin] + [PLK1\_pT210:Wee1\_pT123]. ks\_PLK1 = 155.73e<sup>0.0160T</sup>.

**r54** and **r55**: The Aurora-A inhibitor VX-680 can bind with both the unphosphorylated form (*Aurora-A*) and the phosphorylated form (*AuroraA\_pT288*) of Aurora-A. kb\_AuroraA\_VX =  $1.3 \times 10^{-7}$  (molecule<sup>-1</sup> min<sup>-1</sup>)<sup>46</sup>.

**r56** and **r57**: The PLK1 inhibitor BI-2536 can bind with both the unphosphorylated form (*PLK1*) and the phosphorylated form (*PLK1\_pT210*) of PLK1. kb\_PLK1\_BI =  $6.8 \times 10^{-7}$  (molecule<sup>-1</sup> min<sup>-1</sup>)<sup>47,48</sup>.

(c) Definition of abbreviations used:

: indicates a protein complex;

- \_p\*\* indicates that a protein is phosphorylated;
- <-> indicates a reversible reaction;
- -> indicates an irreversible reaction;

null -> indicates that a species is synthesized;

-> null indicates that a species is degraded.

<sup>(d)</sup> The simulation time was in units of minute. Protein unbinding rates  $k_{ub}$  were set to 0.1 min<sup>-1</sup>, which is of the same order of magnitude as in other mathematical models<sup>2, 3</sup>. The dephosphorylation rates  $k_{dp}$  were set to 0.008 (min<sup>-1</sup>)<sup>49</sup>.

## References

- 1. B. E. McGuinness, M. Anger, A. Kouznetsova, A. M. Gil-Bernabe, W. Helmhart, N. R. Kudo, A. Wuensche, S. Taylor, C. Hoog, B. Novak and K. Nasmyth, *Curr. Biol.*, 2009, **19**, 369-380.
- 2. T. Haberichter, B. Madge, R. A. Christopher, N. Yoshioka, A. Dhiman, R. Miller, R. Gendelman, S. V. Aksenov, I. G. Khalil and S. F. Dowdy, *Mol. Syst. Biol.*, 2007, **3**, 84.
- 3. B. Schoeberl, C. Eichler-Jonsson, E. D. Gilles and G. Müller, *Nat. Biotechnol.*, 2002, **20**, 370-375.
- 4. M. Malumbres and M. Barbacid, *Nat. Rev. Cancer*, 2009, **9**, 153-166.
- 5. J. Pines and T. Hunter, J. Cell Biol., 1991, **115**, 1-17.
- 6. T. Arooz, C. H. Yam, W. Y. Siu, A. Lau, K. K. Li and R. Y. Poon, *Biochemistry*, 2000, **39**, 9494-9501.
- 7. K. A. Merrick, S. Larochelle, C. Zhang, J. J. Allen, K. M. Shokat and R. P. Fisher, *Mol. Cell*, 2008, **32**, 662-672.
- 8. D. Desai, H. Wessling, R. Fisher and D. Morgan, *Mol. Cell. Biol.*, 1995, **15**, 345-350.
- 9. H. Hochegger, S. Takeda and T. Hunt, *Nat. Rev. Mol. Cell Biol.*, 2008, **9**, 910-916.

- 10. L. Parker and H. Piwnica-Worms, *Science*, 1992, **257**, 1955-1957.
- 11. J. R. Pomerening, S. Y. Kim and J. E. Ferrell, *Cell*, 2005, **122**, 565-578.
- 12. N. Watanabe, H. Arai, J. Iwasaki, M. Shiina, K. Ogata, T. Hunter and H. Osada, Proc. Natl. Acad. Sci. USA, 2005, 102, 11663-11668.
- 13. B. Novák, J. J. Tyson, B. Gyorffy and A. Csikasz-Nagy, *Nat. Cell Biol.*, 2007, **9**, 724-728.
- 14. N. Watanabe, H. Arai, Y. Nishihara, M. Taniguchi, T. Hunter and H. Osada, Proc. Natl. Acad. Sci. USA, 2004, 101, 4419-4424.
- 15. A. R. Barr and F. Gergely, J. Cell Sci., 2007, **120**, 2987-2996.
- 16. G. Vader and S. M. Lens, *Biochim. Biophys. Acta*, 2008, **1786**, 60-72.
- 17. V. Archambault and D. M. Glover, Nat. Rev. Mol. Cell Biol., 2009, 10, 265-275.
- 18. T. Takaki, K. Trenz, V. Costanzo and M. Petronczki, *Curr. Opin. Cell Biol.*, 2008, **20**, 650-660.
- 19. W. Chen, M. Wilborn and J. Rudolph, *Biochemistry*, 2000, **39**, 10781-10789.
- 20. R. Boutros, C. Dozier and B. Ducommun, *Curr. Opin. Cell Biol.*, 2006, 18, 185-191.
- 21. R. Boutros, V. Lobjois and B. Ducommun, Nat. Rev. Cancer, 2007, 7, 495-507.
- 22. J. Rudolph, Nat. Rev. Cancer, 2007, 7, 202-211.
- 23. U. Strausfeld, J. C. Labbe, D. Fesquet, J. C. Cavadore, A. Picard, K. Sadhu, P. Russell and M. Doree, *Nature*, 1991, 351, 242-245.
- 24. K. Anderson, J. Yang, K. Koretke, K. Nurse, A. Calamari, R. B. Kirkpatrick, D. Patrick, D. Silva, P. J. Tummino, R. A. Copeland and Z. Lai, *Biochemistry*, 2007, **46**, 10287-10295.
- 25. A. H. Kishore, B. M. Vedamurthy, K. Mantelingu, S. Agrawal, B. A. Reddy, S. Roy, K. S. Rangappa and T. K. Kundu, J. Med. Chem., 2008, 51, 792-797.
- 26. M. G. Manfredi, J. A. Ecsedy, K. A. Meetze, S. K. Balani, O. Burenkova, W. Chen, K. M. Galvin, K. M. Hoar, J. J. Huck, P. J. LeRoy, E. T. Ray, T. B. Sells, B. Stringer, S. G. Stroud, T. J. Vos, G. S. Weatherhead, D. R. Wysong, M. Zhang, J. B. Bolen and C. F. Claiborne, *Proc. Natl. Acad. Sci. USA*, 2007, 104, 4106-4111.
- L. Macůrek, A. Lindqvist, D. Lim, M. A. Lampson, R. Klompmaker, R. Freire, C. Clouin, S. S. Taylor, M. B. Yaffe and R. H. Medema, *Nature*, 2008, 455, 119-123.
- 28. A. Seki, J. A. Coppinger, C.-Y. Jang, J. R. Yates and G. Fang, *Science*, 2008, **320**, 1655-1658.
- 29. A. Seki, J. A. Coppinger, H. Du, C.-Y. Jang, J. R. Yates and G. Fang, J. Cell Biol., 2008, 181, 65-78.
- 30. J. Bartek, C. Lukas and J. Lukas, *Nat. Rev. Mol. Cell Biol.*, 2004, **5**, 792-804.
- 31. J. W. Harper and S. J. Elledge, *Mol. Cell*, 2007, **28**, 739-745.
- 32. J. H. Choi, L. A. Lindsey-Boltz and A. Sancar, Proc. Natl. Acad. Sci. USA, 2007, 104, 13301-13306.
- 33. H. C. Reinhardt and M. B. Yaffe, Curr. Opin. Cell Biol., 2009, 21, 245-255.
- 34. H. Zhao and H. Piwnica-Worms, *Mol. Cell. Biol.*, 2001, **21**, 4129-4139.

- 35. Q. Liu, S. Guntuku, X.-S. Cui, S. Matsuoka, D. Cortez, K. Tamai, G. Luo, S. Carattini-Rivera, F. DeMayo, A. Bradley, L. A. Donehower and S. J. Elledge, *Genes Dev.*, 2000, **14**, 1448-1459.
- 36. D. Branzei and M. Foiani, Nat. Rev. Mol. Cell Biol., 2008, 9, 297-308.
- 37. K. A. Cimprich and D. Cortez, *Nat. Rev. Mol. Cell Biol.*, 2008, **9**, 616-627.
- 38. M. A. Vugt, A. Bras and R. H. Medema, *Cancer Res.*, 2005, **65**, 7037-7040.
- 39. N. Mailand, S. Bekker-Jensen, J. Bartek and J. Lukas, *Mol. Cell*, 2006, 23, 307-318.
- 40. A. Peschiaroli, N. V. Dorrello, D. Guardavaccaro, M. Venere, T. Halazonetis, N. E. Sherman and M. Pagano, *Mol. Cell*, 2006, 23, 319-329.
- 41. M. A. Vugt, A. Bras and R. H. Medema, *Mol. Cell*, 2004, **15**, 799-811.
- 42. A. Krystyniak, C. Garcia-Echeverria, C. Prigent and S. Ferrari, *Oncogene*, 2006, **25**, 338-348.
- 43. Y. Moshe, J. Boulaire, M. Pagano and A. Hershko, Proc. Natl. Acad. Sci. USA, 2004, 101, 7937-7942.
- 44. E. Chan, A. Santamaria, Sillj, Herman and E. Nigg, *Chromosoma*, 2008, **117**, 457-469.
- 45. T. M. Johnson, R. Antrobus and L. N. Johnson, *Biochemistry*, 2008, 47, 3688-3696.
- 46. E. A. Harrington, D. Bebbington, J. Moore, R. K. Rasmussen, A. O. Ajose-Adeogun, T. Nakayama, J. A. Graham, C. Demur, T. Hercend, A. Diu-Hercend, M. Su, J. M. Golec and K. M. Miller, *Nat. Med.*, 2004, **10**, 262-267.
- 47. P. Lenart, M. Petronczki, M. Steegmaier, B. D. Fiore, J. J. Lipp, M. Hoffmann, W. J. Rettig, N. Kraut and J.-M. Peters, Curr. Biol., 2007, 17, 304-315.
- 48. M. Steegmaier, M. Hoffmann, A. Baum, P. Lenart, M. Petronczki, M. Krssak, U. Gurtler, P. Garin-Chesa, S. Lieb, J. Quant, M. Grauert, G. R. Adolf, N. Kraut, J.-M. Peters and W. J. Rettig, *Curr. Biol.*, 2007, **17**, 316-322.
- 49. T. Y. Tsai, Y. S. Choi, W. Ma, J. R. Pomerening, C. Tang and J. E. Ferrell, *Science*, 2008, **321**, 126-129.